MX2021009396A - Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq. - Google Patents
Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq.Info
- Publication number
- MX2021009396A MX2021009396A MX2021009396A MX2021009396A MX2021009396A MX 2021009396 A MX2021009396 A MX 2021009396A MX 2021009396 A MX2021009396 A MX 2021009396A MX 2021009396 A MX2021009396 A MX 2021009396A MX 2021009396 A MX2021009396 A MX 2021009396A
- Authority
- MX
- Mexico
- Prior art keywords
- potentiators
- kcnq
- trifluoroethoxy
- pyridin
- methyl
- Prior art date
Links
- VDRSSRINXUQZRZ-UHFFFAOYSA-N [2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methylurea Chemical class FC(COC1=NC=CC(=C1)CNC(=O)N)(F)F VDRSSRINXUQZRZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 abstract 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002161 motor neuron Anatomy 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 201000002241 progressive bulbar palsy Diseases 0.000 abstract 1
- 201000008752 progressive muscular atrophy Diseases 0.000 abstract 1
- 201000000196 pseudobulbar palsy Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 208000002320 spinal muscular atrophy Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Potenciadores de molécula pequeña de canales de potasio (tales como los potenciadores de Kv7-que son llamados también potenciadores de KCNQ), composiciones que incluyen tales compuestos y métodos para usar tales compuestos para el tratamiento de Esclerosis Lateral Amiotrófica y otras enfermedades neurológicas causadas por cambios en la excitabilidad de neuronas motoras, que incluyen, entre otras, esclerosis lateral primaria, parálisis pseudobulbar, parálisis bulbar progresiva, atrofia muscular progresiva y epilepsia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US201962811038P | 2019-02-27 | 2019-02-27 | |
| PCT/US2020/016499 WO2020163268A1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009396A true MX2021009396A (es) | 2021-09-10 |
Family
ID=69743945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009396A MX2021009396A (es) | 2019-02-06 | 2020-02-04 | Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11208383B2 (es) |
| EP (1) | EP3921030B1 (es) |
| JP (2) | JP7451543B2 (es) |
| KR (1) | KR20210126040A (es) |
| CN (1) | CN113692304B (es) |
| AU (1) | AU2020218180A1 (es) |
| BR (1) | BR112021015544A2 (es) |
| CA (1) | CA3128975A1 (es) |
| DK (1) | DK3921030T3 (es) |
| ES (1) | ES2968807T3 (es) |
| FI (1) | FI3921030T3 (es) |
| HR (1) | HRP20240012T1 (es) |
| HU (1) | HUE064734T2 (es) |
| IL (1) | IL285113B1 (es) |
| LT (1) | LT3921030T (es) |
| MX (1) | MX2021009396A (es) |
| PL (1) | PL3921030T3 (es) |
| PT (1) | PT3921030T (es) |
| RS (1) | RS65040B1 (es) |
| SA (1) | SA521422733B1 (es) |
| SG (1) | SG11202108599SA (es) |
| SI (1) | SI3921030T1 (es) |
| SM (1) | SMT202400003T1 (es) |
| WO (1) | WO2020163268A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009396A (es) * | 2019-02-06 | 2021-09-10 | Lilly Co Eli | Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq. |
| CN115702141A (zh) | 2020-06-25 | 2023-02-14 | 爱杜西亚药品有限公司 | 环丁基-脲衍生物 |
| WO2023054626A1 (ja) * | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | シクロプロパンアミド誘導体 |
| EP4433472A1 (en) | 2021-11-19 | 2024-09-25 | Icagen, LLC | Pyridine compounds as kv7.2 enhancers |
| CN118525003A (zh) | 2021-11-19 | 2024-08-20 | 伊卡根有限责任公司 | 作为kv7.2抑制剂的新型杂芳基脲化合物 |
| EP4452944A1 (en) | 2021-12-22 | 2024-10-30 | Icagen, LLC | Cyclopropyl compounds |
| JP2025506201A (ja) | 2022-02-15 | 2025-03-07 | アイカジェン・エルエルシー | 新規なビシクロペンタン誘導体 |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
| IT202200024963A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9808042A (pt) * | 1997-03-25 | 2000-03-08 | Astra Pharma Prod | Composto, composição farmacêutica, e, processo para preparação de compostos. |
| CN100345823C (zh) * | 2003-01-14 | 2007-10-31 | 赛特凯恩蒂克公司 | 化合物、组合物及方法 |
| RU2006139933A (ru) | 2004-04-13 | 2008-05-20 | Икаген, Инк. (Us) | Полициклические пиридины как модуляторы калиевых ионных каналов |
| US7879839B2 (en) * | 2004-07-29 | 2011-02-01 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| ES2786298T3 (es) * | 2011-03-03 | 2020-10-09 | Zalicus Pharmaceuticals Ltd | Inhibidores de benzimidazol del canal de sodio |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| CA2903288C (en) | 2013-03-15 | 2021-09-21 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| JP6577479B2 (ja) | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
| US9809544B2 (en) | 2014-10-24 | 2017-11-07 | Ono Pharmaceutical Co., Ltd. | KCNQ2-5 channel activator |
| WO2017183723A1 (ja) | 2016-04-22 | 2017-10-26 | 小野薬品工業株式会社 | Ｋｃｎｑ２～５チャネル活性化剤 |
| MX2021009396A (es) * | 2019-02-06 | 2021-09-10 | Lilly Co Eli | Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq. |
-
2020
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en active Application Filing
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
- 2020-02-04 CA CA3128975A patent/CA3128975A1/en active Pending
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 AU AU2020218180A patent/AU2020218180A1/en active Pending
- 2020-02-04 KR KR1020217028040A patent/KR20210126040A/ko active Pending
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
- 2020-02-04 SM SM20240003T patent/SMT202400003T1/it unknown
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 CN CN202080012797.0A patent/CN113692304B/zh active Active
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 IL IL285113A patent/IL285113B1/en unknown
-
2021
- 2021-08-05 SA SA521422733A patent/SA521422733B1/ar unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US12344584B2/en active Active
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11840516B2 (en) | 2023-12-12 |
| PL3921030T3 (pl) | 2024-05-06 |
| AU2020218180A1 (en) | 2021-08-19 |
| JP2024063191A (ja) | 2024-05-10 |
| CN113692304B (zh) | 2025-03-18 |
| IL285113B1 (en) | 2025-06-01 |
| HUE064734T2 (hu) | 2024-04-28 |
| LT3921030T (lt) | 2024-01-25 |
| CA3128975A1 (en) | 2020-08-13 |
| PT3921030T (pt) | 2024-01-12 |
| HRP20240012T1 (hr) | 2024-03-29 |
| SI3921030T1 (sl) | 2024-03-29 |
| BR112021015544A2 (pt) | 2021-10-26 |
| JP7451543B2 (ja) | 2024-03-18 |
| FI3921030T3 (fi) | 2024-01-08 |
| US11208383B2 (en) | 2021-12-28 |
| RS65040B1 (sr) | 2024-02-29 |
| ES2968807T3 (es) | 2024-05-14 |
| US20240076269A1 (en) | 2024-03-07 |
| JP2022519744A (ja) | 2022-03-24 |
| US12344584B2 (en) | 2025-07-01 |
| US20200247752A1 (en) | 2020-08-06 |
| EP3921030A1 (en) | 2021-12-15 |
| US20220073464A1 (en) | 2022-03-10 |
| DK3921030T3 (da) | 2024-01-02 |
| SMT202400003T1 (it) | 2024-03-13 |
| WO2020163268A1 (en) | 2020-08-13 |
| SA521422733B1 (ar) | 2024-02-08 |
| EP3921030B1 (en) | 2023-10-11 |
| SG11202108599SA (en) | 2021-09-29 |
| CN113692304A (zh) | 2021-11-23 |
| IL285113A (en) | 2021-09-30 |
| KR20210126040A (ko) | 2021-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009396A (es) | Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq. | |
| MXPA05012840A (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades. | |
| MX2021006283A (es) | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. | |
| WO2007053844A8 (en) | Compositions and methods for treating inflammatory disorders | |
| MX2007000051A (es) | Derivados de pirimidina fusionados y composiciones de los mismos como moduladores del receptor cxcr3, utiles en la prevencion y tratamiento de trastornos y enfermedades inflamatorias e inmunoregulatorias. | |
| TN2011000220A1 (en) | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | |
| WO2007104783A3 (en) | 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators | |
| WO2008064018A8 (en) | Thienopyrimidinones for treatment of inflammatory disorders and cancers | |
| WO2004078144A3 (en) | Diphenylethylene compounds and uses thereof | |
| WO2001056990A3 (en) | Pyridine derivates as potentiators of glutamate receptors | |
| UA100126C2 (en) | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones | |
| TNSN07323A1 (en) | Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors | |
| MX2010002538A (es) | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas. | |
| TW200505862A (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| WO2008002596A3 (en) | Adenosine a2a receptor antagonists | |
| MX2007000044A (es) | Compuestos, composiciones y metodos de tetrahidroquinazolin-4(3h)- ona-relacionados y tetrahidropirido [2,3-d] pirimidin-4(3h)-ona- relacionados para su uso. | |
| MXPA05010630A (es) | Compuestos de benzopirano utiles para tratar estados inflamatorios. | |
| MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| ZA202200660B (en) | Process for the preparation of ridinilazole and crystalline forms thereof | |
| WO2006028963A3 (en) | Substituted heterocyclic compounds and uses thereof | |
| WO2018071315A3 (en) | Piperidine derivatives as liver x receptor beta agonists, compositions, and their use | |
| WO2006097768A3 (en) | Treatment of intestinal conditions by a compound which causes rna interference | |
| MX2007002525A (es) | Compuestos de difeniletileno y usos de los mismos. | |
| WO2006057945A3 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados |